Greenlight Biosciences Holdings Stock Current Valuation
Valuation analysis of Greenlight Biosciences helps investors to measure Greenlight Biosciences' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Greenlight Biosciences Holdings Company Current Valuation Analysis
Greenlight Biosciences' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Greenlight Biosciences Current Valuation | 90.5 M |
Most of Greenlight Biosciences' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Greenlight Biosciences Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Greenlight Biosciences Holdings has a Current Valuation of 90.5 M. This is 99.37% lower than that of the Biotechnology sector and 98.05% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.46% higher than that of the company.
Greenlight Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Greenlight Biosciences' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Greenlight Biosciences could also be used in its relative valuation, which is a method of valuing Greenlight Biosciences by comparing valuation metrics of similar companies.Greenlight Biosciences is currently under evaluation in current valuation category among its peers.
Greenlight Fundamentals
| Return On Equity | -3.67 | |||
| Return On Asset | -0.82 | |||
| Operating Margin | (14.94) % | |||
| Current Valuation | 90.5 M | |||
| Shares Outstanding | 151.68 M | |||
| Shares Owned By Insiders | 42.90 % | |||
| Shares Owned By Institutions | 26.85 % | |||
| Number Of Shares Shorted | 1.03 M | |||
| Price To Book | 2.14 X | |||
| Price To Sales | 41.41 X | |||
| Revenue | 6.38 M | |||
| Gross Profit | (87.22 M) | |||
| EBITDA | (153.99 M) | |||
| Net Income | (167.06 M) | |||
| Cash And Equivalents | 44.13 M | |||
| Cash Per Share | 0.36 X | |||
| Total Debt | 80.48 M | |||
| Debt To Equity | 2.30 % | |||
| Current Ratio | 1.16 X | |||
| Book Value Per Share | 0.14 X | |||
| Cash Flow From Operations | (136.73 M) | |||
| Short Ratio | 0.78 X | |||
| Earnings Per Share | (1.12) X | |||
| Target Price | 0.6 | |||
| Number Of Employees | 10 | |||
| Beta | 1.44 | |||
| Market Capitalization | 45.43 M | |||
| Total Asset | 148.6 M | |||
| Retained Earnings | (420.64 M) | |||
| Working Capital | 35.75 M | |||
| Z Score | -6.71 | |||
| Net Asset | 148.6 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Other Consideration for investing in Greenlight Stock
If you are still planning to invest in Greenlight Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Greenlight Biosciences' history and understand the potential risks before investing.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |